Publications
Detailed Information
Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mulder, Christiaan | - |
dc.contributor.author | Rupert, Stephan | - |
dc.contributor.author | Setiawan, Ery | - |
dc.contributor.author | Mambetova, Elmira | - |
dc.contributor.author | Edo, Patience | - |
dc.contributor.author | Sugiharto, Jhon | - |
dc.contributor.author | Useni, Sani | - |
dc.contributor.author | Malhotra, Shelly | - |
dc.contributor.author | Cook-Scalise, Sarah | - |
dc.contributor.author | Pambudi, Imran | - |
dc.contributor.author | Kadyrov, Abdullaat | - |
dc.contributor.author | Lawanson, Adebola | - |
dc.contributor.author | van den Hof, Susan | - |
dc.contributor.author | Gebhard, Agnes | - |
dc.contributor.author | Juneja, Sandeep | - |
dc.contributor.author | Sohn, Hojoon | - |
dc.date.accessioned | 2024-05-14T04:34:16Z | - |
dc.date.available | 2024-05-14T04:34:16Z | - |
dc.date.created | 2024-05-14 | - |
dc.date.issued | 2022-01 | - |
dc.identifier.citation | BMJ GLOBAL HEALTH, Vol.7 No.1 | - |
dc.identifier.issn | 2059-7908 | - |
dc.identifier.uri | https://hdl.handle.net/10371/201745 | - |
dc.description.abstract | Introduction Bedaquiline, pretomanid and linezolid (BPaL) is a new all oral, 6-month regimen comprised of bedaquiline, the new drug pretomanid and linezolid, endorsed by the WHO for use under operational research conditions in patients with extensively drug-resistant tuberculosis (XDR-TB). We quantified per-patient treatment costs and the 5-year budgetary impact of introducing BPaL in Indonesia, Kyrgyzstan and Nigeria. Methods Per-patient treatment cost of BPaL regimen was compared head-to-head with the conventional XDR-TB treatment regimen for respective countries based on cost estimates primarily assessed using microcosting method and expected frequency of each TB service. The 5-year budget impact of gradual introduction of BPaL against the status quo was assessed using a Markov model that represented patient's treatment management and outcome pathways. Results The cost per patient completing treatment with BPaL was US$7142 in Indonesia, US$4782 in Kyrgyzstan and US$7152 in Nigeria - 57%, 78% and 68% lower than the conventional regimens in the respective countries. A gradual adoption of the BPaL regimen over 5 years would result in an 5-year average national TB service budget reduction of 17% (US$128 780) in XDR-TB treatment-related expenditure in Indonesia, 15% (US$700 247) in Kyrgyzstan and 32% (US$1 543 047) in Nigeria. Conclusion Our study demonstrates that the BPaL regimen can be highly cost-saving compared with the conventional regimens to treat patients with XDR-TB in high drug-resistant TB burden settings. This supports the rapid adoption of the BPaL regimen to address the significant programmatic and clinical challenges in managing patients with XDR-TB in high DR-TB burden countries. | - |
dc.language | 영어 | - |
dc.publisher | BMJ PUBLISHING GROUP | - |
dc.title | Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis | - |
dc.type | Article | - |
dc.identifier.doi | 10.1136/bmjgh-2021-007182 | - |
dc.citation.journaltitle | BMJ GLOBAL HEALTH | - |
dc.identifier.wosid | 000740754000002 | - |
dc.identifier.scopusid | 2-s2.0-85122886159 | - |
dc.citation.number | 1 | - |
dc.citation.volume | 7 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Sohn, Hojoon | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordAuthor | treatment | - |
dc.subject.keywordAuthor | tuberculosis | - |
dc.subject.keywordAuthor | health economics | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.